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BACKGROUND: Tumor-derived cytokines play a significant role in the progression of head and neck squamous cell car-
cinoma (HNSCC). Targeting proteins, such as tristetraprolin (TTP), that regulate multiple inflammatory cytokines may in-
hibit the progression of HNSCC. However, TTP’s role in cancer is poorly understood. The goal of the current study was
to determine whether TTP regulates inflammatory cytokines in patients with HNSCC. METHODS: TTP messenger RNA
(mRNA) and protein expression were determined by quantitative real-time–polymerase chain reaction (Q-RT-PCR) and
Western blot analysis, respectively. mRNA stability and cytokine secretion were evaluated by quantitative RT-PCR and
enzyme-linked immunoadsorbent assay, respectively, after overexpression or knockdown of TTP in HNSCC. HNSCC tis-
sue microarrays were immunostained for interleukin-6 (IL-6) and TTP. RESULTS: TTP expression in HNSCC cell lines was
found to be inversely correlated with the secretion of IL-6, vascular endothelial growth factor (VEGF), and prostaglandin
E2 (PGE2). Knockdown of TTP increased mRNA stability and the secretion of cytokines. Conversely, overexpression of
TTP in HNSCC cells led to decreased secretion of IL-6, VEGF, and PGE2. Immunohistochemical staining of tissue microar-
rays for IL-6 demonstrated that staining intensity is prognostic for poor disease-specific survival (P ¼ .023), tumor recur-
rence and development of second primary tumors (P ¼ .014), and poor overall survival (P ¼ .019). CONCLUSIONS: The
results of the current study demonstrated that down-regulation of TTP in HNSCC enhances mRNA stability and promotes
secretion of IL-6,VEGF, and PGE2. Furthermore, high IL-6 secretion in HNSCC tissue is a biomarker for poor prognosis. In as
much as enhanced cytokine secretion is associated with poor prognosis, TTP may be a therapeutic target to reduce multi-
ple cytokines concurrently in patients with HNSCC.Cancer 2011;117:2677–89.VC 2011 American Cancer Society.
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messenger RNA (mRNA) stability.
Cytokines have a significant role in cancer, including roles in malignant transformation, tumor growth, survival,
invasion, angiogenesis, and metastasis.1-3 Several cytokines and proinflammatory factors, including interleukin-1 (IL-1),
IL-4, IL-6, IL-8, IL-10, granulocyte-macrophage colony-stimulating factor(GM-CSF), vascular endothelial growth factor
(VEGF), prostaglandin E2 (PGE2), and cyclooxygenase-2 (COX-2), are up-regulated in cancer.
1,4-6 Some of these mole-
cules mediate the role of inflammation in cancer. By promoting cell proliferation, invasion, and survival, cytokines facili-
tate tumor progression in multiple cancers, including colorectal, breast, head and neck, and non-small cell lung
cancers.3,7,8 Because cytokines play a critical role in tumor progression, their expression is highly regulated at many levels:
messenger RNA (mRNA) transcription, post-transcription, and the initiation of protein translation. Post-transcriptional
regulation of cytokines occurs at different stages such as nuclear export, cytoplasmic localization, stability/degradation,
and translation of RNA into protein.9 RNA-binding proteins (RNA-BPs) are trans-acting factors that regulate these events
by binding cis elements on target mRNA. Cis elements such as adenine and uridine (AU)-rich elements (AREs) are located
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in the 50- and 30-untranslated region (UTR) of mRNA
transcripts. Because cytokine transcripts contain AREs in
their 30UTR, proteins that promote degradation or
stability of transcripts by binding to this region have
therapeutic potential.
Expression of RNA-BPs that regulate cytokine
mRNA stability may be altered in cancer.10,11 In breast
cancer, overexpression of human-related antigen R
(HuR), an RNA-BP that stabilizes mRNA, contributes to
poor prognosis and the increased secretion of VEGF.12
Conversely, in colon cancer, tristetraprolin (TTP), which
decreases mRNA stability, is down-regulated, correlating
with increased COX-2 expression.13 These changes in
RNA-BPs underscore their significance in cancer
progression.
HNSCC is the sixth most common cancer, annually
affecting approximately 500,000 individuals world-
wide.14 The 5-year survival rate is approximately 50%,
primarily because of late detection. HNSCCs secrete mul-
tiple cytokines including VEGF, IL-6, and COX-2.15-18
Because COX-2 and IL-6 inhibitors decrease cell prolifer-
ation and invasion in HNSCC in vitro, cancer therapy
targeted toward tumor-secreted inflammatory cytokines
may inhibit tumor progression.3,17-19 Treating HNSCC
with agents directed at a single cytokine is unrealistic
because of the secretion of multiple cytokines with over-
lapping functions.20-22 Given the importance of cytokines
such as IL-6, PGE2, tumor necrosis factor-a (TNF-a),
VEGF, and epidermal growth factor in HNSCC progres-
sion,3,5,6 down-regulation of multiple cytokines simulta-
neously by targeting a common upstream protein may
inhibit HNSCC progression. However, to our
knowledge, the role of TTP in the regulation of multiple
cytokines has not been investigated in HNSCC. Further-
more, the relation between TTP expression and cytokine
secretion in HNSCC progression has not been
established. In the current study, we investigated whether
TTP regulates multiple inflammatory cytokines in
HNSCC and the significance of the overexpression of one
of these cytokines on tumor progression.
MATERIALS AND METHODS
Cell Culture
The human HNSCC cell lines UM-SCC-1, UM-SCC-5,
UM-SCC -11A, UM-SCC-14A, UM-SCC-17B, UM-
SCC-22B, UM-SCC-74A, and UM-SCC-81B and
OSCC3 cells were cultured as described previously.23,24
UM-SCC-1, UM-SCC-5, UM-SCC-11A, UM-SCC-14A,
UM-SCC-17B, UM-SCC-22B, UM-SCC-74A, and UM-
SCC-81B were validated by genotyping. OSCC3 cells were
obtained from Dr. Peter Polverini at the University of
Michigan and were genotyped in the University of Michi-
gan DNA Sequencing Core. The human papillomavirus
type 16 (HPV-16)-immortalized human oral keratinocyte
cell line (HOK-16B, a generous gift from Dr. No-Hee
Park, University of California at Los Angeles) was main-
tained in low-calcium (Ca2þ) keratinocyte growth medium
(Cascade Biologics, Portland, Ore).25 Primary human oral
keratinocytes (NHK) were cultured in oral keratinocyte
growthmedium (ScienCell, Carlsbad, Calif).
Western Blot Analysis
Whole-cell lysates were prepared by sonicating cell sus-
pensions on ice, and Western blot analysis was performed
as described.24 Membranes were blocked and incubated
in the primary antibody overnight at 4C or for 1 hour at
room temperature. Antibody concentrations were as fol-
lows: rabbit anti-TTP (Abcam, Cambridge, UK) at a dilu-
tion of 1:2000, actin (Cell Signaling Technology, Inc,
Danvers, Mass) at a dilution of 1:3000, and horseradish
peroxidase-conjugated donkey antirabbit immunoglobu-
lin (Ig) G and goat antimouse secondary antibodies (dilu-
tions of 1:2000 to 1:5000; Jackson ImmunoResearch
Laboratories, Inc, West Grove, Pa). Immunoreactive pro-
teins were observed using the SuperSignal West Pico
Chemiluminescent Substrate system (Pierce, Rockford,
Ill) and exposed to x-ray film.
Quantitative-Real-Time-Polymerase Chain
Reaction
Total RNA was isolated from cells with QIAzol (Qiagen,
Valencia, Calif). Complementary DNA (cDNA) was syn-
thesized using SuperScript II (Invitrogen, Carlsbad,
Calif). Quantitative real-time polymerase chain reaction
(Q-RT-PCR) was performed with SYBR Green Master
Mix on an Applied Biosystems ABI 7500 RealTime PCR
System (Applied Biosystems, Foster City, Calif). Data
were analyzed using the delta-delta cycle threshold
method with normalization to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) and then expressed rela-
tive to NHK.
Adenoviral Infection and IL-1b Induction
A DL3 replication-deficient serotype-5 adenovirus (Ad-5)
containing cytomegalovirus (CMV)-b–galactosidase (gal)
and human TTP were generated through the University
of Michigan Vector Core as described.26 The cell lines
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UM-SCC-11A and UM-SCC-17B and OSCC3 cells
(35  104) were transduced with 1000 multiplicity of
infection (MOI) Ad-5–b-gal or Ad-5–TTP in serum-free
media. Three hours after transduction, 10% fetal bovine
serum (FBS) was added. Twenty-one hours later,
HNSCC cell lines were serum starved for 4 hours and
incubated with 1 ng/mL of IL-1b or phosphate-buffered
saline (PBS) in serum-free media. Conditioned media
were collected after 24 hours.
Enzyme-Linked Immunoadsorbent Assay for
IL-6, VEGF, and PGE2.
Conditioned medium from NHK, HOK-16B, OSCC3,
and HNSCC cell lines (UM-SCC-1, UM-SCC-11A,
UM-SCC-14A, UM-SCC-17B, UM-SCC-22B, UM-
SCC-74A, and UM-SCC-81B) was processed as
described.27 The total cell number was measured with a
trypan blue enumeration assay. IL-6 and VEGF secreted
into the medium were measured by a noncompetitive
enzyme-linked immunoadsorbent assay (ELISA) whereas
PGE2 was measured using a competitive ELISA (R&D
Systems, Minneapolis, Minn).
Transient TTP Knockdown
The UM-SCC-1, UM-SCC-22B, and UM-SCC-81B cell
lines were transfected with ON-TARGET plus TTP
(Zfp36) SMART Pool (Dharmacon Inc, Lafayette, Colo)
small interfering RNA (siRNA). The UM-SCC-1 cell line
was transfected with Nucleofectin (Amaxa Biosystems,
Gaithersburg, Md) as described.23,28 The UM-SCC-22B
and UM-SCC-81B cell lines (25  104 in 6 well dishes)
were transfected with 1 lg of siRNA using Lipofectomine
RNAimax (Invitrogen), as described.29 Four hours after
transfection, 10% FBS was added. Conditioned media
and whole-cell lysates were collected as described earlier.
Stable TTP Knockdown and mRNA Decay
For stable knockdown of TTP, the UM-SCC-1 and UM-
SCC-22B cell lines were infected with short hairpin RNA
(shTTP and sh vesicular stomatitis virus glycoprotein
[VSVG] control) in lentiviral particles in a VSVG back-
bone (University of Michigan Vector Core). Stable cell
lines were selected in 10 lg/mL of puromycin (Sigma
Chemical Company, St. Louis, Mo). For mRNA decay
experiments, 35 104 cells were plated in 60-mm dishes.
The next day, the cells were serum starved for 4 hours and
treated with 10 nM of actinomycin D for 0, 1, 2, and 3
hours (Sigma Chemical Company). After incubation,
cells were washed with PBS and RNA was harvested.
Invasion Assay
In vitro cell invasion was determined according to the
manufacturer’s instructions (BD Biosciences, Franklin
Lakes, NJ), as described previously.23,28 Cells were
washed and plated on Matrigel-coated inserts at 2.5 to
3.5  104 cells in Dulbecco modified Eagle medium
(DMEM) in triplicate. For control experiments, cells
were plated in DMEM on identical inserts that were not
coated with Matrigel. The lower chamber contained
DMEM with 10% FBS as a chemoattractant. After incu-
bation for 24 hours, cells that had migrated to the lower
surface of the membrane were fixed and stained with 10%
methanol and crystal violet. To determine the percentage
invasion, the average number of cells per field on the inva-
sion inserts was divided by the average number of cells per
field on the control inserts and multiplied by 100.
Migration Assay
Cells were plated at 95% density in 24-well plates in trip-
licate. Twenty-four hours after plating, cells were serum
starved for 6 hours, then treated with 25 mM of mitomy-
cin C (Sigma Chemical Company) for 2 hours in serum-
free conditions. Media was removed and a scratch was
made with a 200-lL pipette tip. Immediately after the
scratch, complete media with 25 mmol of mitomycin C
was added and 3 fields in each replicate were photo-
graphed at 0 hours and at 24 hours. The area between the
migration fronts was determined using ImagePro Plus 5.1
(Media Cybernetics Inc, Bethesda, Md) and the percent-
age migration at 24 hours was calculated.
University of Michigan Oral Cavity/
Oropharyngeal Cancer Organ
Preservation Trial
This randomized clinical trial of patients with stage III/IV
HNSCC (TNM staging system) compared patients
treated concurrently with chemotherapy and radiotherapy
versus those treated with surgery and radiotherapy after
induction chemotherapy.30 A tissue microarray (TMA)
constructed from pretreatment specimens from this clini-
cal trial was used for immunhistochemical studies after
Institutional Review Board approval.
Immunohistochemistry
Immunodetection in tissue sections was performed as
described24 with affinity-purified anti-IL–6 (R&D
Systems; 25 lg/mL), affinity-purified TTP antibody
(Abcam; 3 lg/mL), or the corresponding IgG controls at
the same concentrations.
TTP Regulates Cytokines in NNSCC/Van Tubergen et al
Cancer June 15, 2011 2679
Statistical Analysis
Statistical analysis of in vitro assays was performed using a
Student t test or 1-way analysis of variance (ANOVA). A
P value <.05 was considered to be statistically significant.
For analysis of TMA data, interpretation and scoring
were performed by a board certified pathologist, as
described.23,28 The covariates of interest were T classifica-
tion and N classification, which were analyzed as ordinal
data. The outcomes of interest were overall survival, dis-
ease-specific survival (DSS), time to indication of surgery
at the primary tumor site, and time to disease recurrence
or the development of second primary tumors. The Spear-
man correlation coefficient was used to evaluate univariate
associations between markers and numerical and ordinal
variables of interest. The Cox proportional hazards model
was used to relate time-to-event outcomes to marker levels
and other numerical and ordinal covariates. Statistical
analyses of TMA data were performed using SAS statisti-
cal software (version 9.0; SAS Institute Inc, Cary, NC). A
2-tailed P value .05 was considered to be statistically
significant.
RESULTS
TTP Is Down-Regulated in HNSCC
TTP expression was evaluated by quantitative real-time–
PCR and normalized to GAPDH. The TTP transcript
was lower in 6 HNSCC cell lines compared with NHK
(Fig. 1A) (P < .05, Student t test). The UM-SCC-11A
and UM-SCC-22B cell lines had significantly more TTP
mRNA than NHK (P < .05, Student t test). Whole-cell
lysates from 9 HNSCC cell lines and from 2 nonmalig-
nant cell lines NHK and immortalized keratinocytes
(HOK-16B, designated as IHOK) were immunoblotted
with anti-TTP antibody. As shown in Figure 1B (immu-
noblot and densitometric analyses), TTP expression was
higher in NHK and IHOK compared with HNSCC cell
lines when normalized to actin as a loading control.
Figure 1. Tristetraprolin (TTP) is down-regulated in head and neck squamous cell carcinoma (HNSCC) cell lines. (A) Total RNA
was isolated from normal human keratinocytes (NHK), HOK-16B immortalized keratinocytes (IHOK), and HNSCC cell lines. Com-
plementary DNAs (cDNAs) were prepared and quantitative real-time–polymerase chain reaction was performed using SYBR
Green Master Mix (Applied Biosystems, Foster City, Calif). (B) Whole-cell lysates from NHK, IHOK, and HNSCC cell lines were
electrophoresed and immunoblotted with TTP antibody. Actin was used as a loading control. TTP expression was quantified by
densitometry, normalized to actin and then to NHK, and expressed as the percentage change. (C, D, and E) Conditioned media
from NHK, IHOK, and HNSCC cell lines was collected at 24 hours (*indicates P < .001 compared with NHK). Enzyme-linked immu-
noadsorbent assay experiments were performed in triplicate with similar results.
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OSCC3 cells expressed the least amount of TTP com-
pared with NHK (83% reduction), whereas the UM-
SCC-81B cell line demonstrated the least reduction in
TTP expression compared with NHK. There was an over-
all decrease in TTP expression of 62% (standard deviation
[SD], 24.6%) in HNSCC cell lines compared with NHK.
IL-6, VEGF, and PGE2 were quantified by ELISA
in conditioned media from normal and IHOK and
HNSCC cells to correlate TTP expression with cytokine
secretion. In 7 of the 11 HNSCC cell lines, IL-6 secretion
was found to be significantly up-regulated (*indicates P<
.001, 1-way ANOVA for all cell lines noted) in HNSCC
cell lines compared with NHK. VEGF and PGE2, the
other 2 cytokines evaluated, demonstrated a similar trend.
The increase in VEGF secretion was significant in 8 of 9
HNSCC cell lines (*indicates P< .001, 1-way ANOVA).
The increase in PGE2 secretion was significant in 5 of 9
HNSCC cell lines (P < .001, 1-way ANOVA). Of the
cell lines evaluated, NHK secreted the least VEGF and
PGE2 (Figs. 1D and 1E, respectively). IHOK demon-
strated increased VEGF and PGE2 secretion compared
with normal cells, but less than that observed in the
HNSCC cell lines. The UM-SCC-81B cell line secreted
high levels of all 3 cytokines evaluated, despite high TTP
expression in these cell lines (Fig. 1B). However, in the
majority of cell lines (>65%), TTP expression was found
to be inversely correlated with cytokine secretion.
Overexpression of TTP Reduces Cytokine
Secretion in HNSCC
Three HNSCC cell lines with approximately 50%
reduced endogenous TTP expression compared with
NHK (Fig. 1B) were used for overexpression studies. To
verify TTP overexpression, whole-cell lysates were gener-
ated from HNSCC cell lines transduced with Ad-5 that
contained either TTP or b-gal (control) and were immu-
noblotted for TTP. As shown in Figure 2A, TTP was
overexpressed in the UM-SCC-11A cell line UM-SCC-
17B cell line, and OSCC3 cells transduced with Ad-5–
TTP compared with cells transduced with control vector.
IL-1b is secreted by inflammatory cells adjacent to a
tumor and activates the p38 mitogen-activated protein
kinase (MAPK) pathway within tumor cells.31 Mitogen-
activated protein kinase-activated protein kinase 2
(MK2), the downstream target of p38 MAPK, inactivates
TTP by phosphorylation.32,33 Therefore, we investigated
the effect of TTP on cytokine secretion in the presence
and absence of IL-1b. In mock-transduced cells, IL-1b
increased cytokine secretion in all 3 cell lines, which is
consistent with inactivation of residual TTP. However,
overexpression of TTP led to a significant reduction in
IL-6, VEGF, and PGE2 secretion in all 3 cell lines (Figs.
2B, 2C, and 2D) (*indicates P < .001) when compared
with cells transfected with control vector, even in the pres-
ence of IL-1b.
In a complementary approach, TTP expression was
down-regulated by RNA interference (RNAi) in 3
HNSCC cell lines representing a spectrum of TTP expres-
sion. Knockdown of TTP, verified by immunoblot analy-
sis, led to increased secretion of IL-6, VEGF, and PGE2
(Fig. 3). In the UM-SCC-1 cell line, small interfering
TTP (siTTP) mediated a significant increase in all 3 cyto-
kines evaluated (Fig. 3A) (P < .05). IL-6 secretion was
increased more than PGE2 secretion in the UM-SCC-
22B cell line (P < .05). VEGF secretion demonstrated a
similar trend (Fig. 3B). In the UM-SCC-81B cell line,
which strongly expresses TTP (Fig. 1A), siTTP also
induced a significant increase in the secretion of IL-6,
VEGF, and PGE2 (Fig. 3C) (P< .05). Collectively, over-
expression and knockdown data suggest that TTP inver-
sely regulates IL-6, VEGF, and PGE2 secretion in
HNSCC.
TTP Regulates Cytokine mRNA Stability
in HNSCC
To determine whether TTP targets cytokine mRNA for
degradation in HNSCC, cells were treated with actinomy-
cin D, which inhibits DNA polymerase. Stable cell lines
with shTTP or shVSVG in the UM-SCC-1 and UM-
SCC-22B cell lines were generated. Knockdown of TTP,
confirmed by immunoblot analysis (Fig. 4A), increased
cytokine mRNA stability. For the UM-SCC-1 cell line,
mRNA transcripts of IL-6 and COX-2 in shTTP-trans-
duced cells remained between 90% and 100% stable over
a 3-hour period. In contrast, in cells transduced with
shVSVG, mRNA transcripts degraded to nearly 50% at 3
hours (Fig. 4B) (P < .05). Similarly, in the UM-SCC-
22B cell line, IL-6 and COX-2 mRNAs were more stable
in cells transduced with shTTP (approximately 100%
after 3 hours) compared with control (shVSVG) cells, in
which IL-6 and COX-2 mRNA were degraded in 3 hours
(Fig. 4C) (P< .05).
Loss of TTP Enhances Invasion and Migration
In HNSCC, invasion and migration facilitate tumor pro-
gression. To determine the functional significance of loss
of TTP, invasion and migration assays were performed
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with the UM-SCC-1 cell line after shRNA-mediated
knockdown of TTP (Fig. 4A). Loss of TTP in the
UM-SCC-1 cell line increased invasion nearly 300% com-
pared with control cells transduced with empty vector (Fig.
5A). Migration assays demonstrated that suppression of
TTP increases cell migration. In the UM-SCC-1 cell line,
the percentage area migrated, normalized to time 0, was
75% in shTTP cells whereas control cells migrated 15%
(Fig. 5B). Similar results for invasion and migration were
observed in the UM-SCC-22B cell line (data not shown).
Figure 2. Overexpression of tristetraprolin (TTP) in head and neck squamous cell carcinoma (HNSCC) cell lines decreases cyto-
kine secretion. (A) The UM-SCC-11A cell line, (B) UM-SCC-17B cell line, and (C) OSCC3 cells were transduced with serotype-5 ade-
novirus containing b-galactosidase (b-gal) (control) or TTP. Cell lysates and conditioned media were harvested. Cell lysates were
electrophoresed and immunoblotted with TTP antibody. Conditioned media was used to quantify interleukin-6 (IL-6), vascular en-
dothelial growth factor (VEGF), and prostaglandin E2 (PGE2) secretion by enzyme-linked immunoadsorbent assay. All experi-
ments were performed in triplicate (*indicates P < .001). Standard error bars are present in all graphs. þ indicates positive; ,
negative.
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Increased IL-6 Secretion Is Correlated With
Human HNSCC Progression
Immunohistochemical studies were performed on normal
epithelial and HNSCC tumor tissue and a TMA of
pretreatment tissue specimens from HNSCC. Normal
epithelial tissue was found to demonstrate strong TTP
staining in the basal one-third of the epithelium (Fig. 6A
Left, indicated by arrows), whereas the invasive epithelial
islands in the HNSCC tissue did not demonstrate strong
TTP staining (Fig. 6A Right, inset). IgG controls were
found to be negative (data not shown). Figure 6B (Top
and Bottom) demonstrates high IL-6 and low TTP stain-
ing within the same HNSCC core. IgG controls were
appropriately negative (data not shown). Low TTP and
high IL-6 intensity were found to be correlated with poor
DSS, (P ¼ .043) (Fig. 6C). In addition, TMA findings
revealed that high IL-6 intensity is prognostic for bad
patient outcomes, specifically poor DSS (P ¼ .023)
(Fig. 6D), tumor recurrence or the development of a sec-
ond primary tumor (P¼ .014) (Fig. 6E), and poor overall
survival (P¼ .019) (data not shown). Thus, these findings
based on a small sample size indicate that IL-6 and TTP
expression are inversely correlated and that IL-6 is associ-
ated with poor patient outcome.
Figure 3. Tristetraprolin (TTP) knockdown induces cytokine secretion in head and neck squamous cell carcinoma cells. (A) The
UM-SCC-1, (B) UM-SCC-22B, and (C) UM-SCC-81B cell lines were transfected with small interfering RNA (siRNA) against TTP or
nontarget (nt) siRNA. Whole-cell lysates were electrophoresed and immunoblotted with TTP antibody. Actin was used as loading
control. Conditioned media was assayed in triplicate for interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), and pros-
taglandin E2 (PGE2) by enzyme-linked immunoadsorbent assay. All experiments were performed in triplicate. Data are represen-
tative of the mean and standard deviation of 3 replicates within an experiment (*indicates P < .05). þ indicates positive; ,
negative.
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DISCUSSION
Changes in oncogenic mRNA stability can alter the pro-
duction of inflammatory cytokines. For example, up-reg-
ulation of HuR, an RNA-BP that stabilizes mRNA,
enhances COX-2 and VEGF production.34,35 This
increase in cytokine production is detrimental because
tumor-derived cytokines facilitate oncogenic phenotypes
such as invasion, proliferation, and survival, thereby pro-
moting tumor growth.1,3,7,13,36 Consistent with this
theory, increased COX-2 production in colon cancer
increases tumor invasion.8 The results of the current study
demonstrate that down-regulation of TTP in HNSCC
stabilizes transcripts and promotes the secretion of multi-
ple cytokines, including IL-6, VEGF, and COX-2, and
increases invasion and migration. Furthermore, IL-6 and
TTP expression are inversely correlated in human
HNSCC tissue. High IL-6 expression is predictive of
poor DSS, tumor recurrence, and the development of sec-
ond primary tumors. On the basis of the findings in this
study performed in a small group of patients, patients
with HNSCC tumors with high IL-6 staining intensity
appear to have a much poorer prognosis than those
patients with tumors expressing IL-6 at low levels.
HNSCC is a disease with a poor prognosis, with 5-
year survival rates of approximately 50%.37 HNSCCs
secrete multiple growth, inflammatory, and angiogenic
factors, including VEGF, IL-6, IL-8, and GM-CSF,
which promote tumor progression.3,4,5 IL-6 promotes
tumor growth in mice by promoting the survival and pro-
liferation of HNSCC cells.2 Other cytokines, such as
VEGF, promote angiogenesis and metastasis.37,38
The critical role of cytokines in the progression of
many cancers makes them an attractive treatment tar-
get.3,4,36,39 In a murine model, IL-6 monoclonal antibod-
ies decreased the size of prostate cancer xenografts
significantly.40 However, targeting individual cytokines is
Figure 4. Tristetraprolin (TTP) knockdown increases cytokine messenger RNA (mRNA) half-life. (A) Whole-cell lysates from the
UM-SCC-1 and UM-SCC-22B cell lines that stably expressed short hairpin vesicular stomatitis virus glycoprotein (shVSVG) or short
hairpin TTP (shTTP) were immunoblotted. (B and C) RNA was purified, complementary DNAs (cDNAs) were prepared, and
quantitative real-time–polymerase chain reaction was performed using SYBR Green Master Mix (Applied Biosystems, Foster City,
Calif). Cycle threshold values for interleukin-6 (IL-6) and cyclooxygenase-2 (COX-2) were normalized to glyceraldehyde-3-phos-
phate-dehydrogenase (GAPDH) and expressed as a percentage of time 0. Data are representative of the mean and standard
deviation of 3 individual experiments (*indicates P < . 05; **, P < .001).
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unlikely to be of therapeutic benefit in humans. For exam-
ple, results from a clinical trial in patients with multiple
myeloma with antibodies against IL-6 indicated that there
was no improvement in clinical outcome for these
patients.39 This suggests that cytokines secreted can com-
pensate for one another and therefore this limits the effect
of an inhibitor specific for each cytokine. Targeting a
common regulatory mechanism for multiple cytokines
such as IL-6, VEGF, and PGE2 in HNSCC may decrease
tumor progression and improve response to treatment.
Cytokine mRNA expression is tightly regulated in
resting cells through continuously active mRNA decay
mechanisms. Induction of mRNA decay via inflammatory
signals facilitates rapid changes in the cellular production
of cytokines through alterations in binding of RNA-BP.41
RNA-BPs regulate multiple cytokines by inducing decay
or inhibiting translation. RNA-BPs may bind to multiple
AREs, possibly contributing to competition for binding.
At least 20 different proteins that can bind to ARE seg-
ments have been identified to date, including TTP, HuR,
butyrate response factor (BRF)-1 and BRF-2, ARE/
poly(U)-binding/degradation factor-1 (AUF-1), T cell in-
tracellular antigen-1 (TIA-1) and T-cell-restricted intra-
cellular antigen-related protein (TIAR). However, only a
subset of RNA-BPs has been shown to influence the sta-
bility or translational efficiency of target mRNAs.
One of the most well-studied RNA-BPs is TTP,
which targets mRNA for rapid degradation by binding to
the AREs in the 30UTR.42 Studies with knockout mice
suggest that TTP is crucial in regulating TNF-a and IL-
6.43 Because TTP regulates mRNAs of multiple inflam-
matory cytokines by increasing turnover and inducing
decay, loss of TTP may lead to the increased production
of multiple cytokines, which may be associated with
tumor progression. In some cancers, such as colon cancer,
loss of TTP contributes to tumor growth by increasing
COX-2, VEGF, or matrix metalloproteinase-1 (MMP-1)
production.12,13,44,45 However, these studies did not eval-
uate how TTP overexpression influences the production
of multiple cytokines. In the current study, we demon-
strated that knockdown of TTP in HNSCC stabilizes the
transcripts of multiple cytokines and enhances invasion
and migration.
Because of the host-tumor microenvironment,
inflammatory mediators, such as IL-1b, produced by
inflammatory cells that are adjacent to the tumor may
activate the p38 MAPK pathway within the tumor cells.31
Therefore, in the current study, we investigated the effect
of TTP on cytokine secretion in the presence or absence
of IL-1b. However, TTP overexpression was found to
decrease the secretion of cytokines regardless of stimula-
tion with IL-1b. Although the absolute value of the reduc-
tion (ie, pg/mL/million cells) was greater with the
addition of IL-1b, the fold decrease in cytokine secretion
Figure 5. Tristetraprolin (TTP) knockdown increases head and
neck squamous cell carcinoma invasion and migration. The
UM-SCC-1 cell line was stably transduced with short hairpin
TTP (shTTP) or short hairpin vesicular stomatitis virus glyco-
protein (shVSVG). (A) Invasion is shown. Transduced cells
were plated in serum-free media on Matrigel-coated inserts
or control inserts. The percentage invasion was calculated.
(B) Migration is shown. The UM-SCC-1 cell line was treated
with 25 mmol of mitomycin C (Sigma Chemical Company, St.
Louis, Mo). Media was removed and a scratch was made. Im-
mediately after the scratch, complete media Dulbecco modi-
fied Eagle medium with 25 mmol of mitomycin C was added
and the cells were photographed at 0 hours and at 24 hours.
Data are representative of 2 independent experiments with 3
replicates within an experiment (*indicates P < .02).
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Figure 6. Interleukin-6 (IL-6) intensity is prognostic for disease-specific survival and tumor recurrence in patients with head and
neck squamous cell carcinoma (HNSCC). (A) Immunohistochemistry was performed on tissue sections of normal human epithe-
lium (Left; bar ¼ 100 lm) and human HNSCC (Right; bar ¼ 1000 lm) with tristetraprolin (TTP) antibody. Arrows indicate staining
in the basal one-third of normal epithelium. Inset: Higher magnification of the outlined box demonstrating invasive epithelium is
shown (bar ¼ 60 lm). Arrow indicates invasive epithelium. (B) Immunohistochemistry was performed on tissue sections of a
human HNSCC tissue microarray with the IL-6 and TTP antibodies. The slides were counterstained with hematoxylin. The top and
bottom panels represent high IL-6 and low TTP staining, respectively, in the same HNSCC tissue section (bars ¼ 100 lm). (C)
Low TTP and high IL-6 are correlated with poor disease-specific survival. Patient groups are indicated by colored lines. Red line
indicates low TTP and low IL-6 (n ¼ 9 patients); yellow line, low TTP and high IL-6 (n ¼ 3 patients); blue line, high TTP and low
IL-6 (n ¼ 11 patients); green line, high TTP and high IL-6 (n ¼ 10 patients). Events (indicated by a drop in the graph lines) were
deaths from HNSCC. Subjects who did not experience the events, such as patients who died of unrelated causes, were censored.
(D and E) High IL-6 intensity is prognostic for (D) poor disease-specific survival and (E) the development of tumor recurrence
and second primary tumors. Patient groups are indicated by colored lines. Red line indicates no IL-6 (n ¼ 6 patients); yellow line,
low IL-6 (n ¼ 19 patients); blue line, medium IL-6 (n ¼ 14 patients); green line, high IL-6 (n ¼ 3 patients). IL-6 intensity is also
prognostic for poor overall survival (data not shown).
after TTP overexpression was greater in unstimulated
compared with IL-1b–treated cells, which is consistent
with inactivation of part of the overexpressed TTP by
IL-1b.
TTP expression was found to be reduced in all
HNSCC cell lines compared with NHK. We observed
that there was a 62% (SD, 24.6%) reduction in TTP
expression in HNSCC compared with NHK. However,
reduced TTP expression was not found to correlate 100%
with increased cytokine secretion in HNSCC cells, which
may be because of phosphorylation-mediated inactivation
of TTP. MK2, the downstream target of p38 MAPK,
phosphorylates TTP at serine sites 52 and 178 and renders
the protein inactive by inducing binding of TTP to 14-3-
3 protein.32,33 We observed that TTP expression was
inversely correlated with cytokine secretion except for the
UM-SCC-81B cell line, which was found to strongly
express TTP but secreted high levels of cytokines. This
may be the result of TTP phosphorylation because active
p38 MAPK, which inactivates TTP by phosphorylation,
is up-regulated in HNSCC. We were unable to immuno-
precipitate TTP using available antibodies, but p38
MAPK is active in this cell line. Collectively, these data
suggest that loss or inactivation of TTP contributes to the
production of multiple cytokines in HNSCC. Because
p38 MAPK can be constitutively active in HNSCC,15 the
results of the current study suggest that inhibition of p38
MAPK in HNSCC would decrease cytokine secretion by
preventing inactivation of TTP.
We also observed that TTP knockdown increased
the secretion of multiple cytokines, but the effects on indi-
vidual cytokines varied. This suggests that other pathways
or multiple RNA-BPs are involved in the regulation of
cytokines and the final effect on secretion may be deter-
mined by a balance among these factors. For example,
TTP overexpression in mouse embryonic fibroblasts iso-
lated from TTP knockout mice decreased VEGF but
increased proliferation, whereas TTP overexpression in
HeLA cells decreased cellular proliferation,12 suggesting
that other proteins may influence proliferation in differ-
ent cell types. These studies underscore the importance of
delineating how cytokines are regulated in the context of a
particular cell or tissue.
IL-6 is a pleiotropic cytokine that functions during
inflammation, immunity, bone metabolism, neural devel-
opment, reproduction, and hematopoiesis.46 Although
epithelial malignancies may have elevated IL-6, to the best
of our knowledge, the presence of tumor-derived IL-6 in
HNSCC has not been investigated in the context of
tumor progression.47 The identification of biomarkers
that are prognostic of poor survival will allow for the selec-
tion of tumors for more aggressive treatment. The current
study findings, derived from a small group of patients,
suggest that HNSCCs with low TTP and high IL-6
expression have poorer DSS than HNSCCs with high
TTP and low IL-6 expression. Similarly, in breast cancer,
down-regulation of TTP is a negative prognostic indicator
associated with increased tumor grade and mortality.12
However, TTP expression may not be the actual prognos-
tic indicator in HNSCC. Our findings with IL-6, inde-
pendent of TTP expression, support this theory.
HNSCCs with high IL-6 expression have poor outcomes,
including poor DSS, tumor recurrence, and the develop-
ment of second primary tumors. Consistent with these
observations, high serum IL-6 in HNSCC patients is cor-
related with poor overall survival and an increase in IL-6
during treatment is associated with tumor recurrence.37,48
Furthermore, high serum IL-6 is associated with resistance
to radiotherapy.49
The results of the current study demonstrate that
loss of TTP in HNSCC increases invasion and cell migra-
tion. Similarly, in breast cancer, invasion is decreased
when TTP expression is re-established.45 The increased
invasion and migration may be because of increased cyto-
kine production or TTP may directly regulate proteins
responsible for migration in HNSCC.42 TTP stabilizes
multiple transcripts that affect invasion and tumor
progression, including VEGF, COX-2, urokinase plas-
minogen activator, MMP-1, and IL-8.13,44,45,50
Given the importance of cytokines in invasion and
proliferation, both of which contribute to HNSCC pro-
gression, disruption of cytokine secretion is an attractive
treatment strategy. However, targeting cancers with a
cocktail of inhibitors is impractical and, as mentioned ear-
lier, targeting individual cytokines, such as monoclonal
antibodies against IL-6 in patients with multiple
myeloma, is ineffective in improving patient survival.36
Therefore, up-regulation of a protein, such as TTP, that
inhibits multiple cytokines is an attractive treatment strat-
egy, particularly if it can be combined with p38 inhibitors,
because p38, which inactivates TTP, is constitutively
active in HNSCC.15 However, because of the importance
of cytokines in the immune response, the potential for sys-
temic immunosuppression as a side effect of p38 inhibi-
tors would be a challenge, particularly because it may
promote tumor progression.51,52 This may be overcome
by strategies that specifically target the treatment to tumor
cells. Future studies will explore the mechanisms by which
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TTP-mediated cytokine secretion regulates tumor pro-
gression and the feasibility of targeting this protein to con-
trol tumor growth.
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